Boston U team lands on efficient method to generate new thyroid cells

Translating this research into human stem cells could lead to the development of therapies, including stem cell and genetic engineering technologies, for people with thyroid disorders.

Boston University researchers have devised an efficient way to produce thyroid cells using genetically modified mouse embryonic stem cells. This could lead to generating human thyroid cells, which could allow for the modeling of thyroid disease and help unravel its causes.

The team cultured mouse embryonic stem cells in the lab and engineered them to express a genetic switch for the gene Nkx2-1, which is involved in thyroid development. Guiding the stem cells through different stages of development, they switched this gene on and off, according to a statement.

They found one time period where activating the gene caused the majority of stem cells to become thyroid cells. This work, published in Stem Cell Reports, is the first step to developing a similar approach using human stem cells, according to the statement.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

Thyroid disorders affect about 10% of the U.S. population, the team said. They include Grave’s disease, caused by an overactive thyroid and Hashimoto’s disease, which can cause hyper- or hypothyroidism. The research could lead to new treatments, stem cell therapies or genetic engineering technologies for people with thyroid disorders.

While the approach had a “high yield” of thyroid cells, it may be useful in generating other cell types, such as lung cells, insulin-producing cells and liver cells, said Laertis Ikonomou, an assistant professor at the Boston University School of Medicine.

Suggested Articles

FDA staff took the action in response to cases of early growth plate closure in children on the retinoic acid receptor gamma agonist.

The CTAD presentation cleared up some questions about the data set without delivering a telling blow for either side of the debate.

The FDA has shot down Enzyvant's RVT-802, a rare immunodeficiency disease candidate, citing manufacturing concerns.